Wellgistics shares surge 12.22% intraday after launching Brenzavvy in $16B SGLT-2 inhibitor market via AI-driven pharmacist education.

Wellgistics (NASDAQ: WGRX) surged 12.22% intraday following the announcement of its commercial launch of diabetes drug Brenzavvy to 6,500+ pharmacies, targeting the $16 billion SGLT-2 inhibitor market. The launch leverages the company’s EinsteinRx AI platform to educate pharmacists and providers on Brenzavvy’s competitive advantages over entrenched drugs like Jardiance, including lower out-of-pocket costs for patients and a new pharmacist-led provider education model. The move addresses suboptimal SGLT-2 inhibitor prescription rates (11.9% adherence to class 1A guidelines) and positions Brenzavvy to capture market share in rural communities with high diabetes prevalence. The AI-driven approach aims to optimize prescribing decisions, enhance patient access, and create revenue opportunities for pharmacists, reinforcing investor optimism about the company’s market expansion and technological differentiation.